MedTrace Logo

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

NCT07221344 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2026-04-15

No results posted yet for this study

Summary

Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.

Conditions

  • Alzheimer Disease
  • Alzheimer Disease, Early Onset

Interventions

DRUG

ARO-MAPT-SC

• single or multiple doses of ARO-MAPT-SC by subcutaneous (SC) injection

DRUG

Placebo

• calculated volume to match active treatment by SC administration

Sponsors & Collaborators

  • Arrowhead Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-18
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07221344 on ClinicalTrials.gov